Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals

被引：101

作者：

Arab-Alameddine, M. ^{[1
,2
]}

Di Iulio, J. ^{[3
]}

Buclin, T. ^{[1
]}

Rotger, M. ^{[3
]}

Lubomirov, R. ^{[3
]}

Cavassini, M. ^{[4
]}

Fayet, A. ^{[1
]}

Decosterd, L. A. ^{[1
]}

Eap, C. B. ^{[5
]}

Biollaz, J. ^{[1
]}

Telenti, A. ^{[3
]}

Csajka, C. ^{[1
,2
]}

机构：

[1] Univ Lausanne, Div Clin Pharmacol & Toxicol, Univ Hosp Ctr, Lausanne, Switzerland

[2] Univ Geneva, Dept Pharmaceut Sci, Clin Pharm Unit, Geneva, Switzerland

[3] Univ Lausanne, Inst Microbiol, Univ Hosp Ctr, Lausanne, Switzerland

[4] Univ Lausanne, Div Infect Dis, Univ Hosp Ctr, Lausanne, Switzerland

[5] Univ Lausanne, Biochem Unit, Cery Hosp, Lausanne, Switzerland

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷 / 05期

关键词：

NONNUCLEOSIDE REVERSE-TRANSCRIPTASE; HIV-INFECTED PATIENTS; PREGNANE-X-RECEPTOR; PLASMA-CONCENTRATIONS; CYP2B6; VARIABILITY; METABOLISM; ALLELE; IDENTIFICATION; POLYMORPHISM;

D O I：

10.1038/clpt.2008.271

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Besides CYP2B6, other polymorphic enzymes contribute to efavirenz (EFV) interindividual variability. This study was aimed at quantifying the impact of multiple alleles on EFV disposition. Plasma samples from 169 human immunodeficiency virus (HIV) patients characterized for CYP2B6, CYP2A6, and CYP3A4/5 allelic diversity were used to build up a population pharmacokinetic model using NONMEM (non-linear mixed effects modeling), the aim being to seek a general approach combining genetic and demographic covariates. Average clearance (CL) was 11.3l/h with a 65% interindividual variability that was explained largely by CYP2B6 genetic variation (31%). CYP2A6 and CYP3A4 had a prominent influence on CL, mostly when CYP2B6 was impaired. Pharmacogenetics fully accounted for ethnicity, leaving body weight as the only significant demographic factor influencing CL. Square roots of the numbers of functional alleles best described the influence of each gene, without interaction. Functional genetic variations in both principal and accessory metabolic pathways demonstrate a joint impact on EFV disposition. Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels.

引用

页码：485 / 494

页数：10

共 36 条

[1]

Barrett JS, 2002, INT J CLIN PHARM TH, V40, P507

[2]

Beal SL., 2008, NONMEM users guides

[3] Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism [J].